New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington State MADISON, Wis. , Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is
MADISON, Wis. , Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on January 31, 2024 .
MADISON, Wis. , Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact ® System in Japan beginning November 30, 2023 .
Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance MADISON, Wis. , Nov. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2024 ended September 30, 2023 . First Quarter Fiscal 2024 Summary Net revenue of
MADISON, Wis. , Oct. 31, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 14 th Annual Jefferies London Healthcare Conference. The management team is scheduled to participate in a presentation with moderated Q&A on Wednesday, November 15 th , 2023 at
MADISON, Wis. , Oct. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2024, ended September 30, 2023 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on November 7, 2023 .
MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).
MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO ( American
Large classrooms and a hybrid, in-person/remote connection option will make it easier for more care providers to remain current on best practices and innovations in radiation therapy New center is part of the company's comprehensive education program which also includes on-site training, online
MADISON, Wis. , Sept. 14, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Tuesday, October 3, 2023 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.